TD Cowen initiated coverage of Jasper Therapeutics with an Outperform rating. The company’s lead asset briquilimab addresses a significant unmet need In chronic spontaneous urticaria, the analyst tells investors in a research note. The firm says there are no approved therapies after antihistamines in n chronic inducible urticaria and patients are largely forced to manage their symptoms via avoidance of triggers.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on JSPR:
- Jasper Therapeutics presents Phase 1b/2a data on briquilimab
- New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia
- Bad News for Jasper Therapeutics, Inc. Stock: This New Risk Has Been Added
- Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments
- Jasper Therapeutics reports Q4 EPS ($1.50), consensus ($1.61)
